Literature DB >> 23920015

External validation of the secondary intracerebral hemorrhage score in The Netherlands.

Charlotte J J van Asch1, Birgitta K Velthuis, Jacoba P Greving, Peter Jan van Laar, Gabriël J E Rinkel, Ale Algra, Catharina J M Klijn.   

Abstract

BACKGROUND AND
PURPOSE: We aimed to validate externally in a setting outside the United States the secondary intracerebral hemorrhage (ICH) score that was developed to predict the probability of macrovascular causes in patients with nontraumatic ICH.
METHODS: Patients with nontraumatic ICH admitted to the University Medical Center Utrecht, the Netherlands, between 2003 and 2011 were included if an angiographic examination, neurosurgical inspection, or pathological examination had been performed. Secondary ICH score performance was assessed by calibration (agreement between predicted and observed outcomes) and discrimination (separation of those with and without macrovascular cause).
RESULTS: Forty-eight of 204 patients (23.5%) had a macrovascular cause. The secondary ICH score showed modest calibration (P=0.06) and modest discriminative ability (c-statistic 0.73; 95% confidence interval, 0.65-0.80). Discrimination improved slightly using only noncontrast computed tomography categorization (c-statistic 0.79; 95% confidence interval, 0.72-0.86).
CONCLUSIONS: The discriminative ability and calibration of the secondary ICH score are moderate in a university hospital setting outside the United States. Clues on noncontrast computed tomography are the strongest predictor of a macrovascular cause in patients with ICH.

Entities:  

Keywords:  angiography; arteriovenous malformation; cerebral hemorrhage

Mesh:

Year:  2013        PMID: 23920015     DOI: 10.1161/STROKEAHA.113.002386

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Developing an algorithm to identify patients with intracerebral haemorrhage secondary to a macrovascular cause.

Authors:  Duncan Wilson; Ayokunle Ogungbemi; Gareth Ambler; Ifan Jones; David J Werring; Hans R Jäger
Journal:  Eur Stroke J       Date:  2017-09-19

2.  Modifying the Intracerebral Hemorrhage Score to Suit the Needs of the Developing World.

Authors:  Ajay Hegde; Girish Menon
Journal:  Ann Indian Acad Neurol       Date:  2018 Oct-Dec       Impact factor: 1.383

3.  Intracranial varix of the transverse-sigmoid dural arteriovenous fistula mimicking a ruptured middle cerebral artery aneurysm: A case report.

Authors:  Kuniyuki Onuma; Kiyoyuki Yanaka; Atsushi Tsukada; Kazuhiro Nakamura; Yuji Matsumaru; Eiichi Ishikawa
Journal:  Surg Neurol Int       Date:  2022-03-25

4.  Small vessel disease burden and intracerebral haemorrhage in patients taking oral anticoagulants.

Authors:  David J Seiffge; Duncan Wilson; Gareth Ambler; Gargi Banerjee; Isabel Charlotte Hostettler; Henry Houlden; Clare Shakeshaft; Hannah Cohen; Tarek A Yousry; Rustam Al-Shahi Salman; Gregory Lip; Martin M Brown; Keith Muir; H R Jäger; David J Werring
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-03-19       Impact factor: 10.154

5.  Diagnostic yield and accuracy of CT angiography, MR angiography, and digital subtraction angiography for detection of macrovascular causes of intracerebral haemorrhage: prospective, multicentre cohort study.

Authors:  Charlotte J J van Asch; Birgitta K Velthuis; Gabriël J E Rinkel; Ale Algra; Gérard A P de Kort; Theo D Witkamp; Johanna C M de Ridder; Koen M van Nieuwenhuizen; Frank-Erik de Leeuw; Wouter J Schonewille; Paul L M de Kort; Diederik W Dippel; Theodora W M Raaymakers; Jeannette Hofmeijer; Marieke J H Wermer; Henk Kerkhoff; Korné Jellema; Irene M Bronner; Michel J M Remmers; Henri Paul Bienfait; Ron J G M Witjes; Jacoba P Greving; Catharina J M Klijn
Journal:  BMJ       Date:  2015-11-09

6.  The cost-utility of CT angiography and conventional angiography for people presenting with intracerebral hemorrhage.

Authors:  Richard I Aviv; Adam G Kelly; Babak S Jahromi; Curtis G Benesch; Kate C Young
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.